Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Human gene therapy methods - 1 Apr 2013

Louis Jeune Vedell, Joergensen Jakob A, Hajjar Roger J, Weber Thomas

Abstract excerpt

Adeno-associated virus (AAV)-based vectors are promising tools for gene therapeutic applications, in part because AAVs are nonpathogenic viruses, and vectors derived from them can drive long-term transgene expression without integration of the vector DNA into the host genome. AAVs are not strongly immunogenic, but they can, nonetheless, give rise to both a cellular and humoral immune response. As a result, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral
Share to Capsid Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dependovirus

Share to Immunity, Cellular

Share to Immunity, Humoral

Share to Seroepidemiologic Studies

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 23442094
DOI: 10.1089/hgtb.2012.243
PMCID: PMC3732124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.PMID 23442094Read ↗

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsSemantic proximity Read ↗

Humoral immune responses to AAV gene therapy in the ocular compartmentSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Understanding and Tackling Immune Responses to Adeno-Associated Viral VectorsSemantic proximity Read ↗

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive PatientsSemantic proximity Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Challenges in Humoral Immune Response to Adeno-Associated Viruses DeterminationSemantic proximity Read ↗

Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus VectorsSemantic proximity Read ↗

Human Immune Responses to Adeno-Associated Virus (AAV) VectorsSemantic proximity Read ↗

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene TransferSemantic proximity Read ↗

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.